

PCFA
**Prostate
Cancer
Clinical
Trials**



Prostate Cancer
Foundation of Australia



Who are we?

We are Australia's largest independent charity **exclusively dedicated** to funding prostate cancer research, awareness and support.

We have invested over **\$50 million** in research since 2008, including ground-breaking projects such as the ProPSMA and TheraP clinical trials, and the current **EVOLUTION** Phase II Clinical Trial.

**Our research makes
ground-breaking discoveries.**

The ProPSMA Study

Discovered that PSMA PET/CT is superior to conventional imaging, leading to the listing of PSMA scanning for Australian men.

The TheraP Project

Discovered that a new form of nuclear medicine, known as LuPSMA, is more effective than traditional forms of treatment in beating lethal forms of prostate cancer.

The EVOLUTION Clinical Trial

Is seeking to discover whether immunotherapy can be made effective in combination with LuPSMA for men with terminal prostate cancer.



ONE OF THE GREAT CHALLENGES OF OUR TIME

Today:

**66 men will be diagnosed
Around 10 men will die**

Tomorrow:

**1 in 5 Australian men
diagnosed in their lifetime**

This year:

**24,217 cases
3,507 deaths**

Right now:

**240,000 Australian men
living with the disease**




Our research portfolio

Our **Prostate Cancer Future Fund** invests in Australia's best researchers, best projects, and best cancer clinical centres.

Our research grants portfolio includes The PCFA **Priority Impact Research Award Scheme**, which delivers near-term benefits for men affected by the disease today, to save lives tomorrow.

With a five-year survival rate of 95%,
the answer is within our reach.

2023 PCFA
PIRA GRANTS



Targeting Epigenetic Changes in Advanced Prostate Cancer

Garvan Institute of Medical Research

This project will help identify new epigenetic drivers of treatment-resistant neuroendocrine prostate cancers, using emerging technologies and pre-clinical models to try and restore men's response to treatment.



Manipulating the Immune Response to Treat Prostate Cancer

*Monash University
Department of Biology*

This project will help to advance more effective and targeted treatments for men with metastatic prostate cancer, using the immune system to eradicate prostate cancer proliferation with CAR T-cell therapy.



A Prostate Cancer Physiological Model for Rapid Drug Testing

University of New South Wales

This project will map the metabolic pathways involved in resistance to a specific type of hormone therapy and target identified pathways with metabolism inhibitors to restore treatment response.



Inequalities in Care & Outcomes for Advanced Prostate Cancer

University of South Australia


This project will investigate therapies for men with metastatic prostate cancer to identify patterns of disadvantage. It will also seek to better understand any adverse events and the survival outcomes, to improve clinical practice.

The EVOLUTION Phase II Clinical Trial
exploring new frontiers in nuclear medicine.

FIVE-YEAR PCFA
CLINICAL TRIALS



Before LuPSMA



After LuPSMA

The EVOLUTION Phase II Clinical Trial

exploring new frontiers in nuclear medicine.

FIVE-YEAR PCFA
CLINICAL TRIALS

Phase II Study of Radionuclide ^{177}Lu -PSMA Therapy Versus ^{177}Lu -PSMA in Combination With Ipilimumab and Nivolumab for Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)




110 Patients Enrolled

Men with terminal prostate cancer are now being treated in the trial



10 National Trial Hospitals

Multiple sites in Brisbane, Sydney, Melbourne, Adelaide, and Perth




The value of research




The cost of treating prostate cancer in Australia

Every year


\$1,359,000,000



The number of Australian men diagnosed is increasing



The number of Australian men with aggressive prostate cancer is rising




THE CHALLENGE


**While survival rates have improved,
many men still die.**

Research holds the key.

SURVIVAL RATES THEN & NOW



NUMBER OF DEATHS




THE OPPORTUNITY

We know the way, we have the will.

All we need is the funding.

CANCER RESEARCH FUNDING IN AUSTRALIA

Contribution by tumour type-specific funders and non-tumour type-specific funders to direct funding of tumour type-specific cancer research projects and programs, 2012–2020



Please help us fix this

Clinical trial partnerships

Your support provides vital support as a **Clinical Trial Partnership** through PCFA's new Prostate Cancer Future Fund, support the delivery of new clinical trials provided under our collaboration with the ANZUP Cancer Trials Group.

We have a long-term agreement with ANZUP for the delivery of new multi-centre Australian-based **prostate cancer clinical trials**. Our portfolio of research with ANZUP includes the ProPSMA, TheraP, and EVOLUTION projects.



Prostate Cancer
Foundation of Australia

The difference you are making

Right now, prostate cancer receives **half** the funding dedicated to other leading forms of cancer. Your support today is helping us close that gap tomorrow, funding **more research**, and building a bigger knowledge base for **new discoveries**. Areas of focus include epigenetics, immunotherapies, nuclear medicines, and theranostics.

With a concentrated investment in prostate cancer research, **we know we can beat this disease.**

OUR ROLE

**Research,
awareness,
support.**

OUR GOAL

Zero deaths in our lifetime.